Infliximab in combination with leflunomide. Part 1

Rennes, Anatole France - Patients with rheumatoid arthritis (RA) who cannot take mathematical operation therapy with Remicade
(Remicade, Centocor) and methotrexate may have other safe alternatives.
“Infliximab alignment with a disease-modifying antirheumatic drug such
as leflunomide [Arava, Aventis Pharmaceuticals] or azathioprine
[Imuran, Prometheus Laboratories] could be an alternative for patients
who do not qualify for methotrexate therapy,” say investigators, led by
Dr Aleth Perdriger (Medical Educational institution, Rennes, France).
Their work appears in the May 2006 income of the Ledger of Rheumatology.
The researchers note that while their retrospective acquisition of 225
patients suggests mathematical operation therapy is safe, the subject
dead body controversial.

The
building block points to several studies in recent age that suggest
therapy with Remicade and leflunomide is limited by adverse events [2,3,4].
In one of the studies, Drs PD Kiely and DM United States President
(St George’s Healthcare NHS Reliance, INSTANCE OFwriter, UK) noise that
widespread use of unit therapy has been limited by these events, which
“are common and in some cases severe.”

In the tense
criticism, Perdriger and colleagues evaluate the safety device of
monoclonal antibody used in assemblage with leflunomide or
azathioprine.
They asked medical building physicians to complete a standardized
questionnaire, and they collected data over a two-month flow.
The researchers analyzed adverse events and the reasons for climb-down.

They
found that anti-TNF compound was used in assemblage with leflunomide in
171 of the 225 patients.
Remicade and azathioprine was used in 54 patients, and the length of
Remicade disclosure was similar in both groups (mean 8.8 months).

This is a part of article Infliximab in combination with leflunomide. Part 1 Taken from "Arava Information" Information Blog